Testing the drug delgocitinib for two types of scarring hair loss
Treatments studied
Part of Skin clinical trials.
This study tests an oral medication called delgocitinib, which targets certain enzymes linked to inflammation, in people with central centrifugal cicatricial alopecia (CCCA) or lichen planopilaris (LPP). It aims to see if the drug is safe and if it changes biomarkers (biological signals) related to these conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had CCCA or LPP for at least 6 months.
- If you are a woman who could become pregnant, you must use effective birth control for 30 days before and 28 days after the study.
- You are generally in good health besides your hair loss condition.
- You have not used certain medications (like steroids, JAK inhibitors, or other hair loss treatments) within the past 4 to 8 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medication called deucravacitinib for people with scarring hair loss (frontal fibrosing alopecia or central centrifugal cicatricial alopecia). It aims to see if the drug can reduce inflammation and stop or slow hair loss.
This trial tests a new medication called brepocitinib to treat lichen planopilaris (LPP), a condition that causes scarring and hair loss on the scalp. The study aims to see if this drug can reduce symptoms and help hair regrow.
This trial tests if a non-ablative laser can help treat scarring alopecia (a type of hair loss where follicles are replaced by scar tissue). Researchers will also study your hair follicles' genes to understand how the laser works. It may be an option if your hair loss has been stable for at least 3 months.
This study tests a new medication called nemolizumab for people with lichen planopilaris (LPP), a type of scarring hair loss. It aims to see if the drug can help reduce scalp itching and improve the condition.
This study tests if the pill abrocitinib can help people with Down syndrome who have atopic dermatitis (eczema) or alopecia areata (patchy hair loss). The goal is to see if it improves their skin or hair with manageable side effects.
This trial tests a cream called delgocitinib for adults with lichen sclerosus in the genital area. It aims to see if the cream can safely and effectively reduce symptoms over 52 weeks.
Hear when a new Central Centrifugal Cicatricial Alopecia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.